CRMD — CorMedix Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1410098 ·
Last close
$4.67
Market Cap
$371.44M
52W High
$13.02
52W Low
$4.64
ADV30
1,856,642
Next earnings
2026-11-12
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 51,264,000 26,749,000 -6,619,000 -14,722,000 917,745,000 355,150,000 456,039,000
Jun 2026 99,307,000 74,502,000 42,910,000 25,988,000 904,052,000 256,692,000 443,219,000
Mar 2026 127,427,000 105,122,000 63,658,000 38,601,000 815,637,000 178,087,000 378,588,000
Dec 2025 128,615,264 107,308,042 59,126,248 14,020,141 826,142,000 144,837,000 420,835,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$312,779,181
Investing CF
$3,788,039
Financing CF
$-9,909,058
CapEx
$-4,923,104
Dividends Paid
—
Buybacks
$-17,484,000
EPS Diluted TTM
$0.69
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-126,708,000
Inventory
$43,144,000
Receivables
$76,706,000
ST Investments
$0
EBIT TTM
$158,212,515
Pretax Income TTM
$134,376,436
Interest Exp TTM
$2,781,999
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$412,492,000
EBITDA
$211,322,000
Free Cash Flow
$288,815,392
Enterprise Value
$162,955,344
Total Cash
$355,150,016
Total Debt
$147,460,000
Shares Out
79,537,626
Trailing EPS
$1.97
Book Value
$5.81
ROE
15.3%
ROA
12.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 311,709,000 150,141,000 163,055,000 826,142,000 420,835,000 405,307,000 175,046,000
Dec 2024 43,472,000 -22,356,000 -17,930,000 118,846,000 34,189,000 84,657,000 -50,615,000
Dec 2023 0 -48,957,788 -46,339,227 82,059,957 11,917,528 70,142,429 -38,409,480
Dec 2022 65,408 -30,623,968 -29,701,705 62,038,259 6,978,523 55,059,736 -24,356,732

TTM Snapshot

Revenues TTM
$462,248,553
NetIncome TTM
$187,172,121
OpCashFlow TTM
—
Assets (Latest)
$904,052,000
Forward EPS
$0.35

Max Pain — expiry 2027-01-15

max pain strike: $3.00 · spot: $4.50 · call oi: 0 · put oi: 1,008

Peers — same industry

TickerNameMarket CapLastDaily %
NIKA NIKA PHARMACEUTICALS, INC $369.14M $0.35 —
PBYI PUMA BIOTECHNOLOGY, INC. $369.13M $7.14 —
SPRY ARS Pharmaceuticals, Inc. $366.93M $3.65 —
CYDY CytoDyn Inc. $366.64M $0.25 —
PEPG PepGen Inc. $365.73M $3.88 —

News headlines (Yahoo Finance, 1h cache)

CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
2026-11-13 17:07 · Yahoo
CorMedix Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:03 · Yahoo
CorMedix (CRMD) Q3 2026 Earnings Call Transcript
2026-11-12 18:00 · Yahoo
What CorMedix (CRMD) Said on Its Q3 Earnings Call
2026-11-12 17:15 · Yahoo
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
2026-11-12 12:50 · Yahoo
CorMedix: Q3 Earnings Snapshot
2026-11-12 12:43 · Yahoo
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
2026-11-10 13:17 · Yahoo
CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
2026-11-10 11:12 · Yahoo
CorMedix stock gains as Heron deal adds four products
2026-11-09 13:59 · Yahoo
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
2026-11-09 12:15 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-18 17:21:30 2026-11-16 Kaplan Myron Dir P - Purchase 4.88 25000 122000